- Home
- CCEL vs OCUP Comparison
CCEL vs OCUP Comparison
Compare CCEL & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- OCUP
- Stock Information
- Founded
- CCEL 1989
- OCUP 2018
- Country
- CCEL United States
- OCUP United States
- Employees
- CCEL N/A
- OCUP N/A
- Industry
- CCEL Managed Health Care
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- OCUP Health Care
- Exchange
- CCEL Nasdaq
- OCUP Nasdaq
- Market Cap
- CCEL 53.9M
- OCUP 53.1M
- IPO Year
- CCEL 1997
- OCUP N/A
- Fundamental
- Price
- CCEL $6.49
- OCUP $1.28
- Analyst Decision
- CCEL
- OCUP Strong Buy
- Analyst Count
- CCEL 0
- OCUP 3
- Target Price
- CCEL N/A
- OCUP $18.67
- AVG Volume (30 Days)
- CCEL 3.6K
- OCUP 92.7K
- Earning Date
- CCEL 10-18-2024
- OCUP 11-11-2024
- Dividend Yield
- CCEL N/A
- OCUP N/A
- EPS Growth
- CCEL N/A
- OCUP N/A
- EPS
- CCEL N/A
- OCUP N/A
- Revenue
- CCEL $31,641,636.00
- OCUP $16,449,000.00
- Revenue This Year
- CCEL $3.70
- OCUP N/A
- Revenue Next Year
- CCEL $10.57
- OCUP $258.69
- P/E Ratio
- CCEL N/A
- OCUP N/A
- Revenue Growth
- CCEL 1.93
- OCUP N/A
- 52 Week Low
- CCEL $3.67
- OCUP $1.15
- 52 Week High
- CCEL $9.50
- OCUP $3.50
- Technical
- Relative Strength Index (RSI)
- CCEL 51.74
- OCUP 46.50
- Support Level
- CCEL $6.29
- OCUP $1.24
- Resistance Level
- CCEL $7.19
- OCUP $1.34
- Average True Range (ATR)
- CCEL 0.33
- OCUP 0.07
- MACD
- CCEL 0.03
- OCUP 0.00
- Stochastic Oscillator
- CCEL 36.89
- OCUP 20.00
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.